Skip to main content

Featured

Is the Billionbrains Garage Ventures Ltd (Groww) IPO a Smart Bet or an Over-Hyped Fintech Play?

Introduction The Bengaluru-based fintech platform Groww (via parent Billionbrains Garage Ventures Ltd ) is set to hit the public markets with an IPO of ₹6,632.30 crores , opening on November 4, 2025 and closing on November 7, 2025 . The price band is fixed at ₹95-₹100 per share , with listing expected on the National Stock Exchange of India (NSE) and Bombay Stock Exchange (BSE) around November 12, 2025 . ( India Today ) In this article I (Tony) will give you a no-fluff, straight-talk breakdown of the offer – what the business is, why it matters, what’s good, what’s risky, how it’s priced – so you can judge whether to apply. I don’t pull punches. Let’s dive in. Company Overview & Business Model Who is Groww? Groww started around 2016–17 as a mutual-fund investing app and over time has expanded into a full digital investment platform offering stocks, derivatives (F&O), IPO access, ETFs , digital gold , US stocks , credit and margin trading . ( Wikipedia ) The founding te...
Post a Comment
Read more
Labels

Rubicon Research IPO 2025: Date, Price Band, GMP, Allotment & Review – Should You Apply?



📅 Rubicon Research IPO 2025 Overview

IPO Details Information
IPO Name Rubicon Research Ltd IPO
IPO Type Book Built Issue
Issue Size ₹1,377.50 Crores
Fresh Issue ₹500.00 Crores (1.03 Cr shares)
Offer for Sale (OFS) ₹877.50 Crores (1.81 Cr shares)
Face Value ₹1 per share
Price Band ₹461 – ₹485 per share
Lot Size 30 shares
Minimum Investment (Retail) ₹14,550
IPO Open Date October 9, 2025
IPO Close Date October 13, 2025
Allotment Date (Tentative) October 14, 2025
Listing Date (Tentative) October 16, 2025
Listing Exchange BSE, NSE
Lead Manager Axis Capital Ltd
Registrar MUFG Intime India Pvt. Ltd.

👉 Source: Official RHP & Chittorgarh IPO Calendar

💡 About Rubicon Research Limited

Founded in 1999, Rubicon Research Ltd is a pharmaceutical company specializing in formulation development, manufacturing, and commercialization of complex generics and differentiated drugs.

As of June 30, 2025, Rubicon holds:

  • ✅ 72 approved products (ANDA & NDA) by the US FDA

  • ✅ 17 products awaiting FDA approval

  • ✅ 63 products under development

Rubicon markets over 350 SKUs to 96 global customers, including major US wholesalers (covering 90% of the market).
It operates 3 manufacturing facilities in India and 2 US FDA-approved R&D centers — one in India and another in Canada.

💪 Rubicon Research Competitive Strengths

  • 🚀 Fast-growing Indian pharma company among peers

  • 💊 Strong R&D pipeline and ANDA filings

  • 🌎 Robust US sales & distribution network

  • 🧬 Data-driven product selection framework

  • ✅ Excellent compliance & cost-efficient manufacturing

  • 👨‍💼 Experienced management team

📈 Rubicon Research Financial Performance

Period Ended Total Income (₹ Cr) PAT (₹ Cr) EBITDA (₹ Cr) Assets (₹ Cr)
30-Jun-2025 356.95 43.30 79.74 1,647.60
FY 2024-25 1,296.22 134.36 267.89 1,451.43
FY 2023-24 872.39 91.01 173.09 1,109.49
FY 2022-23 419.00 -16.89 43.97 749.70

Highlights:

  • Revenue grew 49% YoY

  • Profit rose 48% YoY

  • ROE: 29.02%

  • EBITDA Margin: 20.67%

  • Debt-Equity: 0.73

📊 Rubicon is delivering strong earnings momentum with a healthy margin profile.

🎯 Rubicon Research IPO Lot Size & Investment

Category Lots Shares Amount (₹)
Retail (Min) 1 30 14,550
Retail (Max) 13 390 1,89,150
S-HNI (Min) 14 420 2,03,700
B-HNI (Min) 69 2,070 10,03,950

💰 Objects of the Issue

Purpose Amount (₹ in Millions)
Repayment / prepayment of borrowings 3,100
Inorganic growth via acquisitions —
General corporate purposes —

Rubicon intends to use the net proceeds to reduce debt and fund strategic acquisitions to expand its global footprint.

🧩 Promoter Details

Promoters:

  • General Atlantic Singapore RR Pte. Ltd.

  • Pratibha Pilgaonkar

  • Sudhir Dhirendra Pilgaonkar

  • Parag Suganchand Sancheti

  • Surabhi Parag Sancheti

  • Sumant Sudhir Pilgaonkar

Promoter Holding Pre-Issue Post-Issue
Promoters 77.67% To be updated post-listing

🔎 Should You Apply for Rubicon Research IPO?

Positives:

  • Strong revenue & PAT growth

  • Diversified ANDA portfolio with FDA track record

  • US-focused distribution strength

  • Low debt levels after IPO

Risks:

  • High dependence on the US generic market

  • Regulatory challenges (FDA audits, pricing pressure)

  • OFS reduces promoter skin in the game

Verdict:
If listed near upper price band valuations remain under reasonable P/E levels (~20x), this IPO looks attractive for medium- to long-term investors seeking exposure to a growing pharma formulation player.

🔔 Rubicon Research IPO Timeline

Event Date
IPO Open Oct 9, 2025
IPO Close Oct 13, 2025
Allotment Oct 14, 2025
Refunds Initiation Oct 15, 2025
Shares Credit to Demat Oct 15, 2025
Listing Date Oct 16, 2025

❓ Rubicon Research IPO – Frequently Asked Questions

Q1. What is the Rubicon Research IPO price band?
The price band is ₹461 to ₹485 per share.

Q2. When does Rubicon Research IPO open and close?
It opens on October 9, 2025 and closes on October 13, 2025.

Q3. What is the minimum investment for retail investors?
Minimum investment is ₹14,550 (30 shares).

Q4. When is Rubicon Research IPO allotment date?
Tentatively on October 14, 2025.

Q5. When will Rubicon Research IPO list?
Listing expected on October 16, 2025 on BSE & NSE.

Q6. How to check Rubicon Research IPO allotment status?
You can check via MUFG Intime India IPO Allotment Link after the allotment date.

🔗 Suggested Backlinks (Internal & External)

📢 Pro SEO Tips to Reach 10K+ Views

  1. Post as soon as IPO opens – Google rewards freshness.

  2. Update daily with GMP (Grey Market Premium) – that keyword drives traffic fast.

  3. Share your post link on Reddit (r/IndianStockMarket, r/IPOIndia), LinkedIn, and finance Telegram groups.

  4. Add a Google News sitemap so your posts appear in “Top Stories.”

  5. Include your authorship bio (Google E-E-A-T boost).


Labels:
Location: Kolkata, West Bengal, India

Comments

Post a Comment